Journal
NEUROTHERAPEUTICS
Volume 18, Issue 1, Pages 556-568Publisher
SPRINGER
DOI: 10.1007/s13311-020-00967-7
Keywords
Migraine; botulinum; trigeminal; trigeminovascular; glyceryl trinitrate model; multivalent; neuronal delivery
Funding
- MRC [MR/K022539/1]
- MRC Confidence in Concept award [MC_PC_ 16058]
- Migraine Research Foundation
- Finnish Academy [325392]
- Kazan Federal University [0671-2020-0059]
- MRC CASE studentship
- Italian Ministry of Health
- MRC [MR/K022539/1, MC_PC_16058] Funding Source: UKRI
Ask authors/readers for more resources
Migraine, with a prevalence of 15%, is the most common and disabling neurological disorder. Current oral medications have variable effects and intolerable side effects, leading to dissatisfaction. Injectable therapeutics provide a new treatment paradigm for chronic migraine but are effective in only around 50% of subjects.
With a prevalence of 15%, migraine is the most common neurological disorder and among the most disabling diseases, taking into account years lived with disability. Current oral medications for migraine show variable effects and are frequently associated with intolerable side effects, leading to the dissatisfaction of both patients and doctors. Injectable therapeutics, which include calcitonin gene-related peptide-targeting monoclonal antibodies and botulinum neurotoxin A (BoNT/A), provide a new paradigm for treatment of chronic migraine but are effective only in approximately 50% of subjects. Here, we investigated a novel engineered botulinum molecule with markedly reduced muscle paralyzing properties which could be beneficial for the treatment of migraine. This stapled botulinum molecule with duplicated binding domain-binary toxin-AA (BiTox/AA)-cleaves synaptosomal-associated protein 25 with a similar efficacy to BoNT/A in neurons; however, the paralyzing effect of BiTox/AA was 100 times less when compared to native BoNT/A following muscle injection. The performance of BiTox/AA was evaluated in cellular and animal models of migraine. BiTox/AA inhibited electrical nerve fiber activity in rat meningeal preparations while, in the trigeminovascular model, BiTox/AA raised electrical and mechanical stimulation thresholds in A delta- and C-fiber nociceptors. In the rat glyceryl trinitrate (GTN) model, BiTox/AA proved effective in inhibiting GTN-induced hyperalgesia in the orofacial formalin test. We conclude that the engineered botulinum molecule provides a useful prototype for designing advanced future therapeutics for an improved efficacy in the treatment of migraine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available